ASH 2014 - CLL

Interim Analysis of Phase 2 ICLL01: Ofatumumab and High-Dose Methylprednisolone in Patients at Highest Risk for Relapsed/Refractory CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

ONO-4059: A New Oral, Selective BTK Inhibitor for Patients with High-Risk CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Results from the CLL11 Study: Salvage Therapy with Obinutuzumab plus Chlorambucil in Patients with CLL and Comorbidities

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Dose De-Escalation in Fit, Older Patients with CLL: Balancing Efficacy, Safety, and Tolerability

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Update from the RESONATE Trial: Ibrutinib versus Ofatumumab in Relapsed/Refractory CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

The Benefit of Adding Rituximab to Ibrutinib in Relapsed/Refractory CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Interim Analysis of the PROLONG Study: Ofatumumab Maintenance Therapy in Patients with Relapsed CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Ibrutinib Salvage in Relapsed CLL After Allogeneic Transplantation

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Final Results from the CLL20 Study: Alemtuzumab plus Dexamethasone in Very High–Risk Patients with CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Ibrutinib-Based Regimens for Patients with Relapsed/Refractory CLL: Impact of Complex Karyotype

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Page 2 of 3

1
2
3